10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

PYGM Antibody (C-term) Blocking Peptide

Synthetic peptide
Catalog # BP1450b

Specification

PYGM Antibody (C-term) Blocking Peptide - Product Information

Primary Accession P11217

PYGM Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 5837

Other Names
Glycogen phosphorylase, muscle form, Myophosphorylase, PYGM

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP1450b was selected from the C-term region of human PYGM. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

PYGM Antibody (C-term) Blocking Peptide - Protein Information

Name PYGM (HGNC:9726)

Function
Allosteric enzyme that catalyzes the rate-limiting step in glycogen catabolism, the phosphorolytic cleavage of glycogen to produce glucose-1-phosphate, and plays a central role in maintaining cellular and organismal glucose homeostasis.

PYGM Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

PYGM Antibody (C-term) Blocking Peptide - Images

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

PYGM Antibody (C-term) Blocking Peptide - Background

PYGM catalyzes and regulates the breakdown of glycogen to glucose-1-phosphate. Defects in PYGM are the cause of glycogen storage disease type 5 (GSD5), also known as McArdle disease. GSD5 is a metabolic disorder resulting in myopathy characterized by exercise intolerance, cramps, muscle weakness and recurrent myoglobinuria.

PYGM Antibody (C-term) Blocking Peptide - References

Tsoi, S.C., et al., J. Soc. Gynecol. Investig. 10(8):496-502 (2003).Bruno, C., et al., Neuromuscul. Disord. 12(5):498-500 (2002).Hadjigeorgiou, G.M., et al., Neuromuscul. Disord. 12(9):824-827 (2002).Deschauer, M., et al., Mol. Genet. Metab. 74(4):489-491 (2001).Kubisch, C., et al., Hum. Mutat. 12(1):27-32 (1998).